ストックスクリーナーアプリを入手
1.43
3.38%
-0.05
アフターアワーズ：
1.48
0.05
+3.50%
前日終値:
$1.48
開ける：
$1.46
24時間の取引高:
159.94K
Relative Volume:
0.87
時価総額：
$22.75M
収益：
$345.00K
当期純損益:
$-11.25M
株価収益率:
-1.9814
EPS:
-0.7217
ネットキャッシュフロー:
$-16.70M
1週間 パフォーマンス:
-11.18%
1か月 パフォーマンス:
+5.93%
6か月 パフォーマンス:
+33.64%
1年 パフォーマンス:
+71.44%
1日の値動き範囲:
$1.37
$1.4672
1週間の範囲:
$1.37
$1.639
52週間の値動き範囲:
$0.7687
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
名前
Allarity Therapeutics Inc
セクター
電話
401-426-4664
住所
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.43 | 23.55M | 345.00K | -11.25M | -16.70M | -0.7217 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-28 | 開始されました | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc (ALLR) 最新ニュース
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ALLR Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineNet Profit Margin - newsline.com
ALLR Maintained by Ascendiant Capital -- Price Target Raised to $10.25 - GuruFocus
Allarity Therapeutics (ALLR) Slides 5.3% as Stock Tests Critical Support LevelGap Fill Strategy - newsline.com
Are medical stocks lagging Allarity Therapeutics, Inc. (ALLR) this year? - MSN
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance
Amended and Restated Management Services Agreement Between Allarity Therapeutics, Inc. and Ljungaskog Consulting AB Effective June 1, 2026 - Minichart
Allarity Therapeutics Updates CEO Management and Compensation Agreement - TipRanks
Allarity (NASDAQ: ALLR) updates CEO pay and severance terms - Stock Titan
Number of shareholders of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
ALLR Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Advances PipelineGuidance Downgrade Alert - The Legal Advocate
Allarity Therapeutics (ALLR) Faces Selling Pressure, Holds Above Key SupportVolatility Smile - thelegaladvocate.com
Allarity Therapeutics (ALLR) Slides 4.8% in Session; Key Support Levels in FocusGEX Level - newsline.com
Allarity Therapeutics (ALLR) Surges 6.6% as Volume Picks Up, Testing Key ResistanceOption Breadth - The Legal Advocate
Allarity (ALLR) Posts Q1 2026 Earnings Beat — Here's What Drove ItPre-Announcement Alert - The Legal Advocate
Allarity (ALLR) Delivers Q1 2026 Beat — EPS $-0.17 vs $-0.22 ExpectedEarnings Season Preview - The Legal Advocate
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
Allarity Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Allarity Therapeutics Advances Stenoparib Development for Cancer Treatments and Strengthens Financial Position - Quiver Quantitative
Allarity Therapeutics Q1 net loss per share narrows - TradingView
U.S. VA backs trial of Allarity cancer drug for relapsed lung patients - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Allarity Therapeutics (ALLR) posts Q1 2026 loss but lifts cash with $20M notes - Stock Titan
Allarity Therapeutics (ALLR) CEO receives 200,000-share RSU equity grant - Stock Titan
Why Allarity (ALLR) Just Dropped -1.30% — What to Watch 2026-05-14Trade Entry - newser.com
Director Jesper Hoeiland receives 25,000-share grant at Allarity (ALLR) - Stock Titan
Director Jesper Hoeiland joins Allarity Therapeutics (ALLR) with initial Form 3 filing - Stock Titan
Allarity Therapeutics Advances Stenoparib, a Dual PARP and WNT Inhibitor with DRP® Companion Diagnostic, in Phase 2 Cancer Trials - Minichart
Allarity Highlights Stenoparib Progress in New Investor Presentation - TipRanks
Allarity details stenoparib data, CEO to speak in Europe | ALLR 8-K Filing - Stock Titan
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm - The Manila Times
Allarity Therapeutics CEO Thomas Jensen to Speak at Precision Medicine Forum Europe 2026 - Quiver Quantitative
Allarity CEO to outline cancer drug trial work at Stockholm forum - Stock Titan
Director at Allarity Therapeutics (ALLR) receives 45,000 RSUs in grant - Stock Titan
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
Allarity Therapeutics Advances Stenoparib Toward Phase 3 and FDA Approval in Ovarian Cancer with Manufacturing Milestone - Minichart
Stenoparib Phase 3 manufacturing on track as Allarity (NASDAQ: ALLR) preps trials - Stock Titan
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - Investing News Network
Allarity advances stenoparib manufacturing for pivotal trial By Investing.com - Investing.com South Africa
Allarity advances stenoparib manufacturing for pivotal trial - Investing.com India
Allarity readies ovarian cancer drug with no more manufacturing cash due - Stock Titan
What Allarity (ALLR) is doing to earn customer loyalty (Institutional Demand) 2026-05-05Inverse ETF Flow - newsline.com
[ARS] Allarity Therapeutics, Inc. SEC Filing - Stock Titan
Allarity Therapeutics (NASDAQ: ALLR) details 2026 votes on ELOC, pay and equity plan - Stock Titan
Equity grant gives Allarity Therapeutics (ALLR) officer 133,333 RSUs - Stock Titan
Allarity Therapeutics (ALLR) CFO awarded 150,000 restricted stock units - Stock Titan
USPTO allows Allarity (NASDAQ: ALLR) stenoparib DRP patent with exclusivity to 2039 - Stock Titan
Allarity receives USPTO patent notice for stenoparib diagnostic - Investing.com UK
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Investing News Network
Allarity Therapeutics Inc (ALLR) 財務データ
収益
当期純利益
現金流量
EPS
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):